NCT06541730

A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects

A Phase Ic Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DA-302168S Tablets in Overweight/Obese Subjects After Multiple Oral Administration

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Chendu DIAO Pharmaceutical Group CO., LTD. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of continuous oral administration of DA-302168S tablets for 28 days in overweight/obese subjects.

Conditions

• Overweight and Obesity

Interventions

Type	Name	Description
DRUG	DA-302168S	Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
DRUG	Placebo of DA-302168S	Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.

Timeline

• Start date: 2024-08-30
• Primary completion: 2025-01-30
• Completion: 2025-01-30
• First posted: 2024-08-07
• Last updated: 2025-04-16

Locations

1 site across 1 country: China